FDA clears Sequel's insulin delivery system in Type 2 diabetes

The FDA cleared Sequel's Twiist automated insulin delivery system for Type 2 diabetes patients, expanding the product's market availability. This regulatory approval is relevant to HTM professionals supporting diabetes management technologies.